Home Companies Catalysts Deep Dives
Livdelzi seladelpar APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaCVRM
Launch2024-08-14
US LOE2036-08-14
Peak Sales Est$1500M
Formulations[{"id":"livdelzi-tablet","route":"PO","setting":"PATIENT_SELF","frequency":"Once daily","is_primary"
Companies
GILD (ORIGINATOR)100%
Mechanism: ACC inhibitor
Expert: Acetyl-CoA carboxylase inhibitor reducing de novo lipogenesis for NASH/liver disease.
Everyday: Blocks enzyme involved in fat production in the liver.
Targets: ["ACC"]
Revenue History
PeriodRevenue ($M)
Q4 2024$45M
Q1 2025$85M
Q2 2025$120M
Q4 2025$150M
2025$350M
Programs (1)
IndicationStageKey StudyRegional Status
PBCAPPROVEDENHANCE[{"stage":"APPROVED","region":"US","approval_date":"2024-08-14"}]
Upcoming Catalysts (1)
Livdelzi - PBC - Full Approval & EU 2026
Notes
Approved Aug 2024 for PBC. First new PBC drug in years. Strong launch trajectory.
Data from Supabase · Updated 2026-03-24